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Materials and Methods: The inclusion criteria for this multi-center 
prospective study are (1) biopsy-proven NPC, (2) no distant 
metastasis, (3) in clinical remission after curative treatment 
(radiotherapy ± chemotherapy), (4) within 3 year after finishing 
radiotherapy. pEBV DNA concentration is monitored every 3 months. 
Detailed staging workups areperformed when abnormal pEBV DNA 
detected. All tumor recurrences are documented by imaging studies 
along with pathological verification if the lesions are accessible and 
patients agree. 
Results: From August 2011 to October2012, 252 patients were 
enrolled and 33 patients had abnormal pEBV DNA during follow-up 
visit. Thirty of 33 (91%) patients with elevated pEBV DNA have been 
proven as tumor relapse, whereas the remaining 219 patients with 
normal pEBV DNA level are showing no evidence of disease (P<0.0001). 
In addition, two-thirds (20/30) relapsed patients were detected in a 
symptomless state. 
Conclusions: pEBV DNA assay is a very encouraging tool in monitoring 
NPC patients after treatment.  
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Purpose/Objective: Recent studies showed that the dose distribution 
in certain anatomical structures, such as the pharyngeal constrictor 
muscles (PCM), are associated with the risk of radiation-induced 
dysphagia. In the normal swallowing process, larynx elevation and 
tongue retraction also play an important role. However, so far, less 
attention has been paid to the relationship between the dose 
distribution in muscles involved in larynx elevation and tongue 
retraction and the risk of radiation-induced dysphagia. Therefore, the 
purpose of the current study was to investigate the role of the 
radiation dose delivered to the larynx elevation and tongue retraction 
muscles in the development of radiation-induced dysphagia. 
Materials and Methods: This prospective cohort study included 56 
head and neck cancer patients, treated with primary (chemo) 
radiotherapy (CH)RT. In addition to the anatomical structures that 
have been previously identified as swallowing organs at risk (SWOARs), 
such as the PCM superior or supraglottic larynx, muscles involved in 
larynx elevation and tongue retraction were delineated on planning-
CT’s. The larynx elevation complex included an anterior complex, 
including the suprahyoid muscles and thyrohyoid muscle, pharyngeal 
longitudinal muscles and the posterior digastric/ stylohyoid muscles. 
The tongue retraction complex included the genioglossus muscle and 
the tongue base. The primary endpoint was RTOG grade 2-4 dysphagia 
and the secondary endpoints were patient-rated moderate-to-severe 
swallowing problems assessed with the EORTC QLQ-H&N35 
questionnaire, all at 6 months after completing RT of CHRT.  
Results: In the univariate analysis, the mean doses delivered to 
anterior complex (OR=1.116 (95%CI 1.005-1.238)) and longitudinal 
muscles (OR=1.043 (95%CI 1.003-1.085)) were significantly (p≤0.05) 
associated with the primary endpoint. The doses to the anterior 
complex (OR=1.080 (95%CI 1.004-1.162)) and the longitudinal muscles 
were also associated with the risk of moderate-to-severe problems 
with swallowing SOLID food (OR=1.047 (95%CI1.006-1.089)). 
The mean doses delivered to the genioglossus muscle (OR=1.065 
(95%CI 1.002-1.132)) and the base of tongue (OR=1.070 (95%CI 1.005-
1.140)) were also significantly associated with the primary endpoint. A 
significant association was found between the mean dose to the 
genioglossus muscle and problems with swallowing SOLID food 
(OR=1.055 (95%CI 1.002-1.110)). 
Figure 1 shows the NTCP-curves of the risk of grade 2-4 RTOG 
dysphagia and moderate-to-severe problems with solid food as a 
function of the mean dose to these structures. 
 
  
Conclusions: The mean doses delivered to muscles involved in the 
larynx elevation and tongue retraction, as well as the dose to the 
superior PCM and supraglottic larynx, are significantly associated with 
a higher risk of different aspects of radiation-induced dysphagia and 
these structures should also be considered as Swallowing Organs At 
Risk. 
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Purpose/Objective: A wealth of retrospective studies indicate that 
larger tumour volume is a strong prognostic indicator for poor local 
tumour control after (chemo)radiotherapy for laryngeal cancer. The 
impact of tumour volume on the outcome of patients treated within a 
prospective study comparing accelerated radiotherapy (AR) ± 
carbogen breathing and nicotinamide (ARCON) was investigated. 
Materials and Methods: Of 345 patients with cT2-4 laryngeal cancer, 
pre-treatment CT-scans of 270 patients were available for tumour 
volume calculation. Contouring of the primary tumour and involved 
lymph nodes was reviewed by a single head and neck radiation 
oncologist. All living patients had clinical follow-up for a minimum of 
2 years after completion of the treatment. Cox proportional hazard 
models were used for analysis of outcome. 
Results: Of 137 AR and 133 ARCON patients, 57 and 80 vs. 56 and 77 
patients had glottic and supraglottic tumours, respectively (P=0.50). 
Primary tumour and total lymph node volumes were well balanced 
between both treatment arms (P=0.79 and P=0.80, respectively).  
A correlation between the primary tumour volume and T-stage was 
observed (Rs=0.51, P<0.01). In both treatment arms no correlation 
was detected between the primary tumour volume or T-stage and 
